secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001171843-25-007913
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints
--------------------------------------------------------------------------

- Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.
- Cash $10.8M at Sept 30, 2025; raised $3.4M net from ATM post-year-end.
- Phase 3 paridiprubart met primary/secondary endpoints; exploring partnerships.
- Initiated manufacturing for Phase 2 EB06 vitiligo study; recruitment mid-2026.
- Canadian gov't funding extended for respiratory program; JP Morgan meetings planned Jan 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/0001171843-25-007913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/f8k_121125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer